Abstract: A display mounting system including a support column, a moving bracket, an arm assembly, and a tilt assembly is described. The display mounting system includes one or more display attachment brackets to support one or more electronic displays. The display mounting system is used to hold one or more electronic displays over a worksurface or in front of a wall, and it allows the user of the display mounting system to easily change the orientation of one or more electronic displays according to user's preferences.

Abstract: A display mounting system including a support column, a moving bracket, an arm assembly, and a tilt assembly is described. The display mounting system includes one or more display attachment brackets to support one or more electronic displays. The display mounting system is used to hold one or more electronic displays over a worksurface or in front of a wall, and it allows the user of the display mounting system to easily change the orientation of one or more electronic displays according to user's preferences.

Abstract: A lever assembly is for an operating mechanism of an electrical switching apparatus. The electrical switching apparatus includes a number of pairs of separable contacts structured to move from a CLOSED position to a TRIPPED OPEN position in response to a trip condition. The operating mechanism has an enclosure member and a number of biasing elements coupled to the enclosure member. The biasing elements are structured to move the separable contacts from the CLOSED position to the TRIPPED OPEN position. The lever assembly includes a lever member structured to engage the enclosure member, and a component located on the lever member. The component is structured to extend through each of the biasing elements in order to lengthen each of the biasing elements when the separable contacts are in the CLOSED position.

Abstract: A lever assembly is for an operating mechanism of an electrical switching apparatus. The electrical switching apparatus includes a number of pairs of separable contacts structured to move from a CLOSED position to a TRIPPED OPEN position in response to a trip condition. The operating mechanism has an enclosure member and a number of biasing elements coupled to the enclosure member. The biasing elements are structured to move the separable contacts from the CLOSED position to the TRIPPED OPEN position. The lever assembly includes a lever member structured to engage the enclosure member, and a component located on the lever member. The component is structured to extend through each of the biasing elements in order to lengthen each of the biasing elements when the separable contacts are in the CLOSED position.

Abstract: A trip unit wherein one sidewall of a trip unit housing assembly captivates a trip bar is provided. A captivation assembly is coupled, or directly coupled, to a trip unit housing assembly, thereby limiting tolerance buildup. The captivation assembly includes a trip bar bearing cap having a stop feature, thereby limiting tolerance buildup. The trip bar includes a radial stop paddle having hemispherical protrusions structured to contact the trip unit housing, thereby limiting tolerance buildup. The captivation assembly elements are incorporated into the trip unit housing assembly and captivates the trip bar in all but one axis, thereby limiting tolerance buildup and improving repeatability.

Abstract: A trip unit wherein one sidewall of a trip unit housing assembly captivates a trip bar is provided. A captivation assembly is coupled, or directly coupled, to a trip unit housing assembly, thereby limiting tolerance buildup. The captivation assembly includes a trip bar bearing cap having a stop feature, thereby limiting tolerance buildup. The trip bar includes a radial stop paddle having hemispherical protrusions structured to contact the trip unit housing, thereby limiting tolerance buildup. The captivation assembly elements are incorporated into the trip unit housing assembly and captivates the trip bar in all but one axis, thereby limiting tolerance buildup and improving repeatability.

Abstract: A charging handle apparatus includes a two-piece support apparatus that is disposed on a handle assembly and that is engaged with a gear. One of the two pieces is movable with respect to the first piece. The second piece of the support apparatus includes a number of engagement structures that are engaged with the gear and that retain the gear in a given position with respect to the handle assembly. The charging handle apparatus thus can be provided as a pre-assembled component that is readily mountable to a shaft of a circuit interrupter.

Abstract: A charging handle apparatus includes a two-piece support apparatus that is disposed on a handle assembly and that is engaged with a gear. One of the two pieces is movable with respect to the first piece. The second piece of the support apparatus includes a number of engagement structures that are engaged with the gear and that retain the gear in a given position with respect to the handle assembly. The charging handle apparatus thus can be provided as a pre-assembled component that is readily mountable to a shaft of a circuit interrupter.

Abstract: A computer-implemented method for generating a description of a component of an automation system comprises describing the component as a plurality of inputs and outputs, generating a vendor-independent component description file based on a description of the component as the plurality of inputs and outputs, updating the vendor-independent component description file to include vendor-specific hardware information and hardware control logic, and creating the component based on an updated vendor-specific component description.

Abstract: The present invention relates to the polymorphic crystalline hydrochloride salts of a nucleoside valinate ester according to formula Ib, methods of treating diseases mediated by Hepatitis C Virus and pharmaceutical composition containing Ib

Abstract: This invention relates to compounds which are generally muscarinic M2/M3 receptor antagonists and which are represented by Formula I: wherein X, Y, and Z are O, S or NR5, and the other substituents are as defined in the specification; and prodrugs, individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.

Abstract: This invention relates to compounds which are generally muscarinic M2/M3 receptor antagonists and which are represented by Formula I: wherein X, Y, and Z are O, S or NR5, and the other substituents are as defined in the specification; and prodrugs, individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.

Abstract: This invention relates to compounds which are generally muscarinic M2/M3 receptor antagonists and which are represented by Formula I: wherein X, Y, and Z are O, S or NR5, and the other substituents are as defined in the specification; and prodrugs, individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.

Abstract: The present invention relates to the polymorphic crystalline hydrochloride salts of a nucleoside valinate ester according to formula Ib, methods of treating diseases mediated by Hepatitis C Virus and pharmaceutical composition containing Ib.

Abstract: Process and novel intermediates for preparing 2-aminocarboxylic acid esters of the 5-hydroxymethyl group of levovirin (1-(3S,4R-dihydroxy-5S-hydroxymethyl-tetrahydro-furan-2S-yl)-1H-[1,2,4]triazole-3-carboxylic acid amide; Id: R1?R2?R3?H) and acid addition salts thereof. The present process provides the monoesters selectively in high purity with increased efficiency with reduced number of production steps. The process involves condensation of a cyclopentylidene levovirin compound with a N-urethane-N-carboxylic anhydride and subsequent deprotection to directly provide the hydrochloride salt of the product. The mono esters are useful for treatment of viral diseases and are absorbed more efficiently than the parent compound.

Abstract: The present invention relates to the hemisulfate salt of 1-[4(S)-azido-2(S),3(R)-dihydroxy-4-(hydroxymethyl)-1(R)-cyclopentyl]cytosine (Ia) with improved stability and physical properties which facilitate manufacturing, handling and formulating I and polymorphic crystalline forms thereof.

Abstract: The present invention relates to the hemisulfate salt of 1-[4(S)-azido-2(S),3(R)-dihydroxy-4-(hydroxymethyl)-1(R)-cyclopentyl]cytosine (Ia) with improved stability and physical properties which facilitate manufacturing, handling and formulating I and polymorphic crystalline forms thereof.

Abstract: The present invention relates to nucleosides of formula I wherein R1, R2 and R3 are as defined herein that modulateTh1 and Th2 immune activity, methods of using compounds according to formula I, alone or in combination therapy, for treatment of a bacterial or a viral infection, a parasite infestation, a cancer or tumor or an autoimmune disease and compositions containing prodrugs of the nucleoside of formula Ia.

Abstract: This invention relates to compounds which are generally muscarinic M2/M3 receptor antagonists and which are represented by Formula I: 1

Abstract: This invention relates to compounds which are generally muscarinic M2/M3 receptor antagonists and which are represented by Formula I: wherein X, Y, and Z are O, S or NR5, and the other substituents are as defined in the specification; and prodrugs, individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.